LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Harvard Bioscience Inc

Fermé

SecteurSoins de santé

0.66 3.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.63

Max

0.73

Chiffres clés

By Trading Economics

Revenu

1.1M

-1.2M

Ventes

141K

21M

Marge bénéficiaire

-5.978

Employés

330

EBITDA

42K

197K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+203.03% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

321K

26M

Ouverture précédente

-2.47

Clôture précédente

0.66

Sentiment de l'Actualité

By Acuity

50%

50%

185 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Harvard Bioscience Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 nov. 2025, 18:59 UTC

Principaux Mouvements du Marché

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov. 2025, 22:06 UTC

Acquisitions, Fusions, Rachats

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 nov. 2025, 21:40 UTC

Résultats

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov. 2025, 21:40 UTC

Résultats

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov. 2025, 21:39 UTC

Résultats

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov. 2025, 21:38 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 21:38 UTC

Résultats

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov. 2025, 21:10 UTC

Résultats

XP Inc. 3Q EPS BRL2.47 >XP

17 nov. 2025, 21:10 UTC

Résultats

XP Inc. 3Q Rev BRL4.67B >XP

17 nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 nov. 2025, 19:16 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 18:20 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov. 2025, 16:45 UTC

Acquisitions, Fusions, Rachats

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov. 2025, 16:16 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 16:15 UTC

Résultats

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov. 2025, 15:40 UTC

Acquisitions, Fusions, Rachats

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov. 2025, 15:22 UTC

Acquisitions, Fusions, Rachats

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparaison

Variation de prix

Harvard Bioscience Inc prévision

Objectif de Prix

By TipRanks

203.03% hausse

Prévisions sur 12 Mois

Moyen 2 USD  203.03%

Haut 2 USD

Bas 2 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.3 / 0.3401Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

No Evidence

Long Terme

No Evidence

Sentiment

By Acuity

185 / 374Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat